SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Bayer Corporation Release: New Canadian-Led Global Study of Bayer's Xarelto® (rivaroxaban tablet), Initiated for the Secondary Prevention of Cardiovascular Death, Myocardial Infarction and Stroke in Patients With Coronary or Peripheral Artery Disease